X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
ODM-208/MK5684 is an investigational CYP11A1 inhibitor, which is being evaluated in combination with hormone replacement therapy under phase 3 clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): MK5684,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Cophex 2024
Not Confirmed
Contact Supplier
Details:
ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): ODM-208,Glucocorticoid,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $290.0 million
Deal Type: Collaboration July 13, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling pathway.
Lead Product(s): ODM-208,Glucocorticoid,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
ANI’s Fludrocortisone Acetate Tablets are the generic version of the Reference Listed Drug (RLD) Florinef, is a prescription medicine used to treat symptoms of Addison Disease (Adrenocortical Insufficiency) and Salt-Losing Forms of Congenital Adrenogenital Syndrome.
Lead Product(s): Fludrocortisone Acetate
Therapeutic Area: Endocrinology Product Name: Fludrocortisone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
